Stazol (Cilostazol) is a medication indicated for use in managing symptoms associated with chronic circulatory conditions in the lower limbs. The medication is used to help with symptoms of Intermittent Claudication (IC), as observed through an increase in walking distance. The medication is also utilized for managing symptoms associated with chronic Peripheral Arterial Disease (PAD), which are chronic conditions characterized by symptoms that interfere with daily functioning.

The therapeutic focus is to provide support that helps ease the overall symptom burden related to insufficient blood flow. Stazol is applied across domains where additional symptomatic support is needed to address the distressing symptoms of claudication, including muscular pain, cramping, and fatigue in the legs that arise during physical activity. The medication assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

The medication's benefit includes support for the improvement of functional ability. This supportive relief may contribute to an increased distance patients can walk comfortably before discomfort arises. It is generally applied in scenarios where symptoms create noticeable physiological strain and interference with routine activities.

“This medication is considered relevant for easing symptom clusters that interfere with daily comfort and limit an individual's mobility.”

---

Quick Fact: Relief for Lifestyle-Limiting Pain Stazol is commonly used to help patients manage pain, cramping, and fatigue in the leg muscles that become disruptive during walking and create noticeble physiological strain and interference with daily functioning.

Stazol (Cilostazol) is officially indicated for adult patients suffering from symptoms of Intermittent Claudication due to Peripheral Arterial Disease (PAD). Regulatory agencies classify its use as second-line therapy, meaning it is reserved for patients whose symptoms have not sufficiently improved after adopting lifestyle changes like exercise and smoking cessation.

Who Must Not Use Stazol (Contraindications)

The medication is strictly contraindicated in several high-risk groups:

• Heart Failure: Patients with Congestive Heart Failure (CHF) of any severity must not use Stazol.
• Recent Cardiac Events: Prohibited for those with unstable angina, recent myocardial infarction (MI), or coronary intervention within the last six months.
• Bleeding Risk: Contraindicated for individuals with a known predisposition to bleeding, such as active peptic ulceration, a recent hemorrhagic stroke, or those taking two or more additional antiplatelet or anticoagulant agents.

Population-Specific Restrictions

Population Group	Regulatory Status
Pregnancy	Contraindicated / Must not be used.
Breastfeeding	Not recommended.
Pediatric Patients	Safety and efficacy have not been established.
Severe Renal Impairment	Contraindicated (Creatinine Clearance leq 25 mL/min).
Moderate/Severe Hepatic Impairment	Contraindicated (data not available for safe use).

Interactions with other medicines and products

The interaction profile of Stazol (Cilostazol) is defined by its metabolic pathway and its action as an antiplatelet agent, as documented in official regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Stazol is primarily metabolized by the hepatic enzymes CYP3A4 and CYP2C19. Co-administration with inhibitors of these enzymes is officially documented to increase the systemic exposure (AUC and Cmax) of Cilostazol and its active metabolite. For example, the strong CYP3A4 inhibitor Ketoconazole and the CYP2C19 inhibitor Omeprazole are both officially stated to raise drug concentrations significantly.

Combining Stazol with other antiplatelet agents (such as Aspirin or Clopidogrel) or anticoagulants is associated with a risk of additive pharmacodynamic effects, which increases the potential for hemorrhage. In some regulatory jurisdictions, combination with multiple antiplatelet agents is formally contraindicated.

Administration and Substance Constraints

The mandatory administration rule requires Stazol to be taken on an empty stomach, specifically separated by one-half hour before or two hours after meals. This is due to the documented finding that food, particularly high-fat content, significantly increases drug absorption and plasma concentrations. Co-consumption of Grapefruit Juice is advised against, as it acts as an intestinal CYP3A4 inhibitor and is officially documented to increase Cilostazol exposure. In the presence of severe renal or hepatic impairment, the drug's metabolism and clearance are altered, necessitating specific regulatory cautions.

Selective Inhibition of the PDE3 Enzyme

The drug initiates its action by functioning as a selective inhibitor of the enzyme Phosphodiesterase Type 3 (PDE3), a primary molecular target found in both arterial smooth muscle cells and platelets. This inhibition prevents the breakdown of the crucial intracellular messenger, cyclic Adenosine Monophosphate (cAMP), leading to its accumulation.

---

Dual Mechanistic Consequences: Vasodilation and Platelet Inhibition

This rise in cAMP concentration drives a dual physiological cascade: in smooth muscle cells, elevated cAMP reduces intracellular calcium, resulting in vasodilation (arterial widening); in platelets, it suppresses activation signals, resulting in platelet inhibition (reduced clumping). This unique, simultaneous mechanism modulates both the mechanical resistance of the vessels and the fluidity of the blood.

---

Physiological Outcome: Modulation of Peripheral Hemodynamics

The resulting physiological state is defined by altered circulatory dynamics in the periphery. By acting on two distinct regulatory pathways—vascular muscle tone and platelet aggregation—the mechanism works synergistically to both increase the capacity of the blood vessels and limit the tendency of platelet-mediated flow impedance.

The use of Stazol (Cilostazol) follows specific instructions regarding administration route, dosage, timing, and duration. The medication is supplied exclusively as an Oral Tablet in strengths of 50 mg and 100 mg, establishing the oral route as the primary method of administration.

Labeled Dosing Regimen

The standard dosage regimen specifies 100 mg taken twice daily.

Feature	Instruction
Dosing Frequency	Twice daily (b.i.d.).
Timing with Meals	Must be taken on an empty stomach: either 30 minutes before or 2 hours after both breakfast and the evening meal.
Adjusted Dose Rule	The dose is reduced to 50 mg twice daily when the medicine is co-administered with strong or moderate inhibitors of the liver enzymes CYP3A4 or CYP2C19.

Treatment Duration Protocol

A specific timeframe is used for assessing response: if adequate benefit or improvement is not observed after 3 months of therapy, the treatment should be discontinued. Patients who miss a dose should take only the next scheduled dose and should not take a double dose for compensation. No special adjustments to the standard regimen are required for older adults.

Research Evidence / Overview of Studies for Stazol

Evidence for Symptom Management of Intermittent Claudication

The majority of research on Stazol has been conducted using Randomized Controlled Trials (RCTs). These short- to intermediate-term studies are designed to compare the outcome measurements in groups receiving the medicine versus those receiving an inactive substance, known as a placebo. The studies were applied in research exploring how symptoms change over time in adults diagnosed with Intermittent Claudication (IC), a condition marked by functional limitations and muscular pain in the legs that begins during walking.

The research examined outcomes related to physical discomfort by using standardized treadmill tests. These tests monitored physiological strain or stress and provided specific measurements of how far people could walk before pain started (Initial Claudication Distance) and the maximum distance they could walk (Absolute Claudication Distance). The findings describe patterns observed in the studies, including measurements of walking distance metrics in the groups studied over the typical study duration of 12 to 24 weeks. Studies also reported patient-reported outcomes describing perceived discomfort and overall quality of life that were measured in the observed populations.

Research on Secondary and Long-Term Outcomes

Research has explored whether the Major Adverse Cardiovascular Events (MACE) and the rates of all-cause mortality that occurred during the studies differed between groups. For the broader claudication population, findings related to major vascular outcomes or mortality were often inconsistent or derived from studies that were not specifically designed or statistically powered to draw clear conclusions on these serious events.

Research has explored the effects of Stazol beyond the few months covered by the primary efficacy trials. Regulatory bodies have required long-term follow-up studies to observe responses over defined time intervals. Despite these efforts, long-term effects are not fully established. Follow-up durations were limited, and studies sometimes faced the issue that patients did not continue taking the study medication consistently, which can affect the reliability of the long-term data.

Evidence in Specific Patient Populations and Uncertainties

The research reflects patterns observed primarily in adults with stable Intermittent Claudication. Studies monitored different patient groups within the main trials, including those with co-existing conditions, particularly diabetes, and older adults. The results apply only to the populations studied. Data for certain groups, such as those with highly advanced Peripheral Arterial Disease or individuals with fluctuating manifestations of the condition, remain insufficient.

Furthermore, comparative evidence is lacking to definitively describe how Stazol patterns relate to other non-medicinal or therapeutic approaches over a long timeframe. The study results reflect the specific conditions under which they were conducted, and findings describe group patterns rather than providing individual predictions.

Common questions about Stazol (FAQ)

Q: Does Stazol affect blood pressure?

A: Official regulatory documents indicate that Stazol may cause changes in circulatory dynamics. Documented effects include low blood pressure (hypotension) and a faster heart rate, such as palpitations or tachycardia. Official labeling documents note that caution is required when Stazol is co-administered with other medicines that have known blood pressure-lowering effects.

Q: What should I do if I miss a dose of Stazol?

A: Official prescribing information states that if a dose is missed, the next dose should be taken only at the regularly scheduled time. The information specifies that a double dose must not be taken for compensation.

Q: Is Stazol contraindicated for patients with kidney problems?

A: Official labeling states that Stazol is strictly contraindicated (must not be used) in patients who have severe kidney impairment, defined as a creatinine clearance of leq 25, mL/min. Regulatory information indicates that no adjustment to the standard dose is generally required for patients with milder kidney problems.

Q: What should I do if I take too much Stazol (overdose)?

A: If too much Stazol is taken, official sources report that symptoms may include a severe headache, diarrhea, fainting, low blood pressure, and irregularities of the heartbeat. Official safety information advises seeking emergency medical attention immediately if an overdose is suspected.

Q: Can I drive a car while taking Stazol?

A: Official information from regulatory bodies indicates that Stazol can cause dizziness. If dizziness occurs, official product information advises against driving or using tools or heavy machinery.

Q: Where in the body does Stazol start to work?

A: The medicine is taken by mouth and is absorbed into the bloodstream. While the drug’s intended sites of action in the body (such as arterial walls and platelets) are known, the overall amount of the drug absorbed into the system is not fully established.

Q: Are there any side effects that are more common in older patients?

A: Studies noted in regulatory documents have specifically reported that some effects may occur more frequently in older adults (patients over 70 years old). These more common effects in this population include diarrhea and palpitations (a sensation of having a fast or irregular heartbeat).

How to Store and Dispose of Stazol?

This information reflects the official storage, handling, and disposal requirements documented in regulatory drug labeling for the active substance Stanozolol and general pharmaceutical guidelines.

Official Storage and Handling Requirements

Requirement	Official Regulatory Statement
Temperature and Protection	Store at controlled room temperature (e.g., 20 C to 25 C) and protect from moisture.
Handling Constraints	Must be stored and handled following strict security and inventory control due to its classification as a Controlled Substance.
Child Safety	Must be stored out of the reach of children.

Official Disposal Rules

Disposal instructions require that any unused, expired, or rejected product must be destroyed according to written procedures that comply with federal, state, and local regulations for the destruction of a Controlled Substance. This process ensures the product is not diverted and prevents environmental contamination. Regulatory standards mandate that the product's integrity must be maintained up to its expiration date by adherence to these conditions.